Clinical Trial Examines Stent-Free Percutaneous Coronary Intervention for New Lesions
Recent findings from a large clinical investigation suggest that drug-coated balloons may perform comparably to standard drug-eluting stents when treating newly identified coronary artery blockages. Presented at the Transcatheter Cardiovascular Therapeutics annual conference, the TRANSFORM II trial evaluated whether avoiding permanent metallic implants during percutaneous coronary intervention remains a viable approach for selected patients.
Trial Design and Findings
The open-label, multicenter study enrolled participants across Europe, Asia, and Brazil who had native coronary lesions. Researchers randomly assigned individuals to receive either a sirolimus-coated balloon or a standard everolimus drug-eluting stent following successful vessel preparation. The primary endpoint measured target lesion failure at twelve months, encompassing cardiac death, target vessel heart attacks, and ischemia-driven target lesion revascularization.
According to study presenter Bernardo Cortese, MD, MSc, the incidence of target lesion failure reached 2.1 percent in the drug-coated balloon arm compared to 2.4 percent in the stent group. This met the prespecified statistical criteria for noninferiority. Furthermore, secondary outcomes such as net adverse clinical events showed no significant divergence between the two interventions.
Important Considerations and Limitations
Despite the favorable primary outcome, investigators noted specific nuances in the data. While clinically driven revascularization rates were similar, any target lesion revascularization occurred more frequently among participants treated with the coated balloon rather than the stent. Study authors suggested this discrepancy might stem from operator tendencies to re-treat patients if angiographic results appeared less uniform without a permanent metal scaffold, though researchers emphasized these low event numbers warrant cautious interpretation.
Experts also highlighted financial and practical challenges associated with implementing this technology. Panelists at the meeting pointed out that pricing differences and varying healthcare reimbursement policies could influence how hospitals adopt stent-free procedures.
Additionally, investigators outlined several study limitations. The trial excluded patients with severe calcification, complex bifurcations, highly tortuous vessels, and certain acute clinical presentations. Because participating operators hailed from experienced centers, authors noted that findings might require further study before general translation to broader clinical practice. Long-term follow-up is planned to assess outcomes over a five-year horizon.
